Recently, oncolytic adenovirus with a FAP-targeting has displayed an improved anti-tumor immunity through endogenous T cell activation to attack FAP+ stromal cells in tumor-bearing mice models [122, 123]. This evidence concerns the gene FAP and neoplasm.